Suven Life Sciences Ltd (SUVEN) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 530239 | NSE: SUVEN | Pharmaceuticals & Drugs | Small Cap

Suven Life Sciences Share Price

170.15 -1.25 -0.73%
as on 05-Dec'25 16:59

Suven Life Sciences Ltd (SUVEN) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 530239 | NSE: SUVEN | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Suven Life Sciences

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Suven Life Sciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
3,898.9 Cr.
52-wk low:
102.7
52-wk high:
303

Is Suven Life Sciences Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Suven Life Sciences: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Suven Life Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 19.2%21.9%27.6%10%-6.4%-6.8%-8.1%-3%-1%-5.7%-
Value Creation
Index
0.40.61.0-0.3-1.5-1.5-1.6-1.2-1.1-1.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 50054462528614.413.511.813.511.76.76
Sales YoY Gr.-8.8%15%-54.3%-95%-6.5%-12.2%14.4%-13.7%-43%-
Adj EPS 6.4810.42.6-1-1.6-2.4-1.2-0.8-2.3-2.6
YoY Gr.-23.9%29.7%-75%-138.2%NANANANANA-
BVPS (₹) 45.15362.829.128.126.430.239.138.836.647
Adj Net
Profit
8911014335.7-13.6-22.3-38.5-25.4-16.4-50.4-58
Cash Flow from Ops. 89.8147105-12-45.2-36.7-36.6-22.9-20.6-47.4-
Debt/CF from Ops. 0.90.50.3-0.2-0-0-0000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -38.1%-14.3%-17.5%-43%
Adj EPS -189.2%NANANA
BVPS-2.3%5.5%6.7%-5.6%
Share Price -3.4% 27.5% 38.1% 27.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
15.116.317.95.6-3.5-5.7-8.8-3.8-1.9-6.1-6.2
Op. Profit
Mgn %
2630.637.818.2-243.3-222.9-304.6-201.7-263.3-775.4-1025.4
Net Profit
Mgn %
17.820.322.912.5-94.5-165.8-325.3-187.2-139.9-757.3-997.7
Debt to
Equity
0.10.1000000000
Working Cap
Days
1831911933575,1935,2194,0064,3823,6178867,487
Cash Conv.
Cycle
565657811221311329757,125

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Suven Life Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) -2.6 -9.3
TTM Sales (₹ Cr.) 5.9 5.9
BVPS (₹.) 47 12.4
Reserves (₹ Cr.) 1,047 259
P/BV 3.65 13.86
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 102.70 / 303.00
All Time Low / High (₹) 0.55 / 311.92
Market Cap (₹ Cr.) 3,899
Equity (₹ Cr.) 22.8
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Suven Life Sciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Suven Life Sciences - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Suven Life Sciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales50054462528614131214127
Operating Expenses 370378389234504448414358
Manufacturing Costs141151146106282525212132
Material Costs16314715269000000
Employee Cost 36515934151517161721
Other Costs 31293225836556
Operating Profit 13016523652-35-30-37-28-31-52
Operating Profit Margin (%) 25.9%30.4%37.8%18.2%-244.0%-225.0%-308.0%-204.0%-263.0%-778.0%
Other Income 20212327148282111
Interest 6652111000
Depreciation 17212514444776
Exceptional Items 0000004670
Profit Before Tax 12615923063-26-28-36-20-9-47
Tax 26367224-12-500-10
Profit After Tax 10012315839-14-23-36-20-8-47
PAT Margin (%) 20.0%22.7%25.3%13.7%-95.4%-167.0%-306.0%-148.0%-68.5%-707.0%
Adjusted EPS (₹)7.38.911.52.8-1.0-1.6-2.3-0.9-0.4-2.2
Dividend Payout Ratio (%)25%10%12%49%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 623732867402388365476853845798
Share Capital 13131313131315222222
Reserves 611719854389375352461832824776
Minority Interest0000000000
Debt6656332100000
Long Term Debt422622100000
Short Term Debt2430310000000
Trade Payables3638577632225
Others Liabilities 1441381621461091411029945
Total Liabilities 8699641,119557503509580954851809

Fixed Assets

Gross Block325349376397767838878113
Accumulated Depreciation20436817524646515054
Net Fixed Assets 30530630822252138372860
CWIP 710250054000
Investments 23366381359242295426528653714
Inventories83931390000010
Trade Receivables5446623221111
Cash Equivalents 2415210139317415320
Others Assets 1551391831722331481092141514
Total Assets 8699641,119557503509580954851809

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 90147105-12-45-37-37-23-21-47
PBT 12615923063-26-28-36-20-9-47
Adjustment 111310-5-9-3-1-8-22-4
Changes in Working Capital -2010-92-55-7-51653
Tax Paid -27-35-44-15-3-1-1-161
Cash Flow From Investing Activity -62-353-383422-107-349-144
Capex -58-31-42-39-2-6-20-32-37
Net Investments -23-343342117-53-130-1047861
Others 192110-736243-242-8121
Cash Flow From Financing Activity -68-30-525435146396-1-1
Net Proceeds from Shares 000000039700
Net Proceeds from Borrowing -180-251-1-1-1-000
Interest Paid -6-6-5-2-1-1-0-0-0-0
Dividend Paid -25-13-190000000
Others -19-12-46536147-1-1-1
Net Cash Flow -40-23615-411224-22-4

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)16.9918.2219.836.18-3.48-6.02-8.62-3.03-0.94-5.73
ROCE (%)19.2421.8827.589.98-6.4-6.82-8.1-2.97-1.03-5.71
Asset Turnover Ratio0.610.590.60.340.030.030.020.020.010.01
PAT to CFO Conversion(x)0.91.20.66-0.31N/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days34333141625547283372
Inventory Days605968004302226
Payable Days8991114170000000

Suven Life Sciences Ltd Stock News

Suven Life Sciences Ltd FAQs

The current trading price of Suven Life Sciences on 05-Dec-2025 16:59 is ₹170.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Suven Life Sciences stood at ₹3,898.9.
The latest P/E ratio of Suven Life Sciences as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Suven Life Sciences as of 04-Dec-2025 is 3.65.
The 52-week high of Suven Life Sciences is ₹303.0 and the 52-week low is ₹102.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Suven Life Sciences is ₹5.86 ( Cr.) .

About Suven Life Sciences Ltd

Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

Shares are listed at Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange(HSE). It has a state of the art R&D center recognized by Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India. Also, it has world class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Life Science Companies for New Chemical Entities (NCE's).

Business Units

C.R.A.M.S

The company’s main thrust is in Contract Research and Manufacturing Services (C-R-A-M-S). Suven's ‘C-R-A-M-S’ is in existence since 1991 serving as many as 22 global Life Science and Fine Chemical Companies by developing and supplying cost effective Pharmaceutical and Agro Chemical  Intermediates for New Chemical Entities  (NCE's) meeting world standards of Quality, Speed and Respect for Environment.

DDDSS

Drug Discovery & Development Support Services (DDDSS) aims to provide Contract Drug Discovery & Development services in Medicinal chemistry, Process chemistry, Analytical chemistry, In-vitroScreening, DMPK, Brain Microdialysis, CV Safety, In-vivo Metabolic Disorders & CNS Pharmacology, Phase-I Bio-analysis and Discovery Toxicology.

Suven Nishtaa Pharma

Suven Nishtaa Pharma (Suven Nishtaa), a joint venture company of Suven Life Sciences, is a Pharmaceutical Formulations Contract Services provider.

Suven Nishtaa, a 100% Export Oriented Unit, is engaged in providing end-to-end Drug Product Development services, viz.

Products

  • Advanced Intermediates
  • IntermediatesActive
  • Pharmaceutical Ingredients (APIs )
  • Stock Chemicals for Disposal

Milestones

  • 1989  Incorporation as Suven Pharmaceuticals Pvt. Ltd.
  • 1990 Commenced Operations
  • 1991 Expanded into Fine Chemical Intermediates
  • 1992 Commenced export of Fine Chemical Intermediates
  • 1994 Initiation of 'C-R-A-M-S' business model (Contract Research And Manufacturing Services) 
  • 1995 Went Public (IPO)
  • 1996 First sale from 'C-R-A-M-S'
  • 1997 ISO 9002 Certification
  • 1999 Recognition as an Export House
  • 1999 Acquired a Drug Unit at Hyderabad, converted into Research center and Pilot Plant
  • 2001 New Suven Research Center (SRC) inaugurated at Hyderabad
  • 2001 Recognition of SRC as in-house R & D unit by Department of Scientific & Industrial Research (DSIR), India
  • 2001 Borregaard takes equity stake
  • 2002 cGMP Lab at SRC commissioned
  • 2003 Acquired assets of New Jersey, USA based Synthon Chiragenics Corporation
  • 2003 Name changed to Suven Life Sciences Limited
  • 2004 Gets ISO 14001:1996 certification for Unit - 1 (Suryapet) and Unit - 2 (Jeedimetla)
  • 2005 Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan
  • 2005 Suven Awarded Phase III Clinical study for Chronic Low Back pain.
  • 2006 Suven receives National Accreditation Board for Testing and Calibration Laboratories (NABL) certification
  • 2006 Suven and Lilly Establish Drug Discovery Collaboration
  • 2006 Amalgamation of ASIAN CLINICAL TRIALS ( ACT)
  • 2006 All the units got Certification for  ISO 9001 , ISO 14001, OHSAS 18001
  • 2007 Suven Unit III cGMP facility accepted by USFDA for manufacture of API's
  • 2007 Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection
  • 2007 Suven Life Sciences secures two Product Patents in Australia & New Zealand for their New Chemical Entities (NCEs)
  • 2007 Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases.
  • 2007 Suven obtains 1st Product Patent from US Patent office
  • 2008 Suven obtains 2nd Product Patent from US Patent office
  • 2008 Suven Establishes second CNS Drug Discovery Collaboration with Lilly 
  • 2008 Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region) 
  • 2008 Suven Life Sciences gets Two Product patents in Korea and Mexico 
  • 2008 Suven Life Sciences ACT Enters into an Alliance with VPSCRO 
  • 2008 Suven Life Sciences gets Two product patents for NCEs in South Africa and China 
  • 2008 Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride 
  • 2009 US FDA ACCEPTANCE to UNIT- I, Suryapet
  • 2010
    Suven Secures Two product patents in China and Russia
    Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System
    Suven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders.
    Suven Life Secures Three Australian Patents on NCEs
    Suven gets two patents from Japanese Patent Office for NCE's
  • 2011
    Suven's Unit-III receives US FDA Acceptance
    Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world
    Suven Life Sciences bags ""Bio-Excellence Award at Bangalore India Bio 2011
    Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world
    Suven Life Sciences bags Pharmexcil's Gold ""Patent Award""
  • 2012
    Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA
    Suven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and Eurasia
    Suven Life Sciences bags Pharmexcil's ""Platinum Patent Award""
    Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×